The anti-fibrotic agent SMP-534 attenuates bleomycin-induced pulmonary fibrosis in hamsters.
Pulmonary fibrosis is a progressive and lethal lung disease characterized by accumulation of ECM and loss of pulmonary function. However, no cure exists for this disease, and current treatments often fail to slow its progression or relieve its symptoms. We have previously reported that the anti-fibrotic agent SMP-534 has beneficial effects on renal fibrosis in animal model of nephropathy. In this study, we examined whether SMP-534 has beneficial effects on pulmonary fibrosis in bleomycin-treated hamsters. Treatment with SMP-534 [low dose (70 mg/kg) or high dose (110 mg/kg)] counteracted inhibition of body weight increase induced by bleomycin. In addition, SMP-534 significantly inhibited bleomycin-induced increase in lung hydroxyproline level, an index of collagen formation. Moreover, SMP-534 significantly ameliorated histological pulmonary fibrotic changes induced by bleomycin. The results of this study indicate that the anti-fibrotic agent SMP-534 may offer a new therapeutic option for the treatment of pulmonary fibrosis.
Tsujimura
Tsuyoshi
T
Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, Konohana-ku, Osaka, Japan.
Ono-Kishino
Michiko
M
Nagamine
Jun
J
Sugaru
Eiji
E
Tokunaga
Teruhisa
T
Kitoh
Makoto
M
Nagata
Ryu
R
Nakagawa
Tsutomu
T
Taiji
Mutsuo
M
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D001549:Benzamides / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects*; D001835:Body Weight / Q000187:drug effects; D006224:Cricetinae; D003412:Cricetulus; D005109:Extracellular Matrix / Q000378:metabolism; D006801:Humans; D006909:Hydroxyproline / Q000378:metabolism; D008297:Male; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D011897:Random Allocation
D000903:Antibiotics, Antineoplastic; D001549:Benzamides; C505358:SMP-534; D001761:Bleomycin; D006909:Hydroxyproline